LONDON, 2025 — Claritas Intelligence has published its global oculoplastic surgery market report, sizing the market at USD 4.8 billion in 2025 and projecting growth to USD 8.4 billion by 2033, our base case reflecting a 7.2% CAGR over the 2025–2033 study period. The report covers historical data from 2019 and spans therapeutic, pharmacological, and end-user segments across all major geographies.
The single most consequential structural shift the report identifies is the re-medicalization of thyroid eye disease. Teprotumumab's commercial success — a biologic commanding a list WAC exceeding USD 14,000 per infusion cycle — established proof-of-concept that an IGF-1R-targeting biologic could achieve blockbuster-level adoption in a relatively small addressable population. That template has now attracted competitive density unusual even by rare-disease ophthalmology standards. Viridian Therapeutics is running three concurrent Phase 3 trials of VRDN-003 (NCT06625411, NCT06625398, NCT07155668), making it the most advanced subcutaneous anti-IGF-1R candidate in the pipeline. Tourmaline Bio's TOUR006 is in Phase 2 (NCT06088979), and Sling Therapeutics' linsitinib — an oral IGF-1R inhibitor — is in Phase 2b/3 (NCT05276063). The convergence of these programs means 2026–2028 is likely to see multiple NDA/BLA submissions. Each approval adds incremental WAC-level revenue while layering in new gross-to-net complexity; the TED pharmacotherapy sub-segment is forecast at approximately 18% CAGR through 2033 in the Claritas model. The route-of-administration shift from IV to subcutaneous self-injection also carries meaningful channel economics consequences, moving coverage from Medicare Part B to Part D and altering administration-setting economics for payers and providers alike.
Demographic aging constitutes the second structural driver, though its effects are uneven across geographies. Aponeurotic ptosis prevalence rises sharply after age 60, and the global population aged 65 and over is growing at approximately 3% annually across OECD countries, creating structurally expanding procedure volumes in one of oculoplastic surgery's most reimbursed categories. Periocular skin cancer adds another procedural layer: rising basal cell and squamous cell carcinoma incidence in fair-skinned populations in North America, Europe, and Australia generates complex eyelid-reconstruction cases following Mohs clearance, carrying higher average procedure revenue than primary cosmetic blepharoplasty and increasing device content per case. AI-assisted surgical planning is beginning to compress titanium orbital implant design-to-print timelines from days to hours, a workflow change that stands to increase procedure throughput in high-volume reconstructive centers.
North America, led by the United States, holds the largest regional share at 41%. U.S. health expenditure reached USD 13,473 per capita in 2023, approximately 3.2 times the EU average, sustaining a premium pricing environment for oculoplastic biologics and devices that concentrates pipeline investment in FDA-first development strategies. Asia Pacific, with China as the primary growth engine, is the fastest-growing regional market in the Claritas base case, supported by expanding access infrastructure and rising elective and reconstructive procedure volumes.
"The market's headline CAGR masks a genuine bifurcation. The TED biologic segment and the reimbursed reconstructive surgical segment are on materially different growth and pricing trajectories than elective cosmetic procedures, which face both reimbursement reclassification risk and cash-pay channel migration. Analysts modeling oculoplastic surgery as a single curve will misstate segment-level economics — and the linsitinib oral profile, if Phase 2b/3 data are supportive, has the potential to compress the IV and subcutaneous biologics pricing corridor more aggressively than current consensus assumes." — Ananya Sharma, Analyst, Claritas Intelligence
The full report covers twelve companies including AbbVie (Allergan Aesthetics), Viridian Therapeutics, Johnson & Johnson Vision, Alcon Laboratories, Bausch + Lomb, Carl Zeiss Meditec, STAAR Surgical, Sling Therapeutics, Tourmaline Bio, Stryker, Integra LifeSciences, and Medtronic.
About Claritas Intelligence: Claritas Intelligence is a market intelligence publisher specializing in healthcare, pharmaceutical, and medical device sectors, delivering data-driven research to strategy teams, investors, and industry participants worldwide. Our reports combine primary field research, regulatory data, and proprietary modeling to support commercial and investment decision-making.
The full analysis, including segmentation, regional breakdowns, forecasts, and company profiles, is available in the Oculoplastic Surgery Market Report.
“The global oculoplastic surgery market is valued at USD 4.8B in 2025 and the report projects growth to USD 8.4B by 2033 at a 7.2% CAGR, driven by TED biologic pipeline maturation and aging-demographic procedure volumes.”
Ananya Sharma
Senior Research Analyst – Healthcare & Life Sciences